Abstract:Abstract Rationale: As the result of genetic alterations and tumor hypoxia, cancer cells re-program metabolism to meet increased energy demand for enhanced anabolism, cell proliferation, and protection from oxidative damage and cell death signals. Whereas glycolysis and its regulation by the MYC oncogene product (Myc) have been intensively studied, glutaminolysis and anapleurosis, especially under hypoxia, have not been defined. Objectives: We sought to determine whether glutamine, a key source of nitrogen and anabolic carbon skeleton for mammalian cells, is still utilized under hypoxic condition and how it is regulated by MYC. Methods: We used NMR and FT-ICR-MS to resolve 13C and 15N labeling patterns of metabolites derived from labeled glutamine or glucose in the P493 human B lymphoma model that bear a tetracycline-repressible MYC, under normoxic and hypoxic conditions. Levels of specific enzymes, which are involved in glucose and glutamine metabolism, were determined by immunoblotting and LC-MRM-MS and compared with the metabolomic profiles. Measurements and Main Results: Myc regulates almost the entire glycolytic pathway. As expected for hypoxia, many glycolytic enzymes levels and lactate production were elevated, and 13C- glucose catabolism by the TCA cycle was significantly diminished. Myc elevated glutaminase (GLS, which converts glutamine to glutamate and NH4+), the glutamine transporter SLC1A5, and the transaminases GOT1 and GPT2, suggesting that transamination is favored with Myc activation. While GLS-mediated NH4+ release persisted under hypoxia, the Myc-induced transaminases favor the production of α-ketoglutarate without additional NH4+ production. The 13C labeling pattern of Ala is consistent with active mitochondrial GPT2 that transaminates 13C-pyruvate derived from 13C- glucose. Given that mitochondrial function is generally believed to be diminished by hypoxia, glutamine metabolism unexpectedly persisted in hypoxia with continued oxidation of glutamine carbons by the TCA cycle. The key enzymes and main products of 13C labeled glutamine were not decreased by hypoxia, and glutamine contributed to substantial de novo glutathione production in hypoxia. Because glutamine metabolism is sustained in hypoxia, which is pervasive in the tumor microenvironment, we sought to target glutaminase in vivo. We found that small molecule inhibition of glutaminase could diminish lymphoma and pancreatic cancer xenograft growth in vivo. Conclusions: Our studies reveal a previously unsuspected sustained glutamine metabolism in hypoxia. Glutamine contributes to TCA cycle carbons as well as enhances glutathione synthesis in hypoxia, suggesting that cancer cells reprogram metabolism via both glucose and glutamine to adapt to the tumor microenvironment. Our findings indicate that key nodal points in glutamine metabolism in addition to those in glycolysis could be targeted for therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2799. doi:10.1158/1538-7445.AM2011-2799

Glutamine availability regulates cDC subsets in tissue

SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity

Glutamine Deprivation Promotes the Generation and Mobilization of MDSCs by Enhancing Expression of G-CSF and GM-CSF

Differential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells

Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation of MDSCs and reprogramming tumor associated macrophages

Glutamine synthetase expression rescues human dendritic cell survival in a glutamine-deprived environment

A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle

Glutamine addiction in tumor cell: oncogene regulation and clinical treatment

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

Glutamine deficiency in solid tumor cells confers resistance to ribosomal RNA synthesis inhibitors

Abstract 1208: Glutamine Modulates Cellular NAD+/NADH Homeostasis Thereby Regulating Cancer Metastasis, Drug Sensitivity in Cancer Cells

Glutamine deprivation alters TGF-β signaling in hepatocellular carcinoma

Abstract 2799: Unexpected Sustained Hypoxic Glutamine Metabolism and Therapeutic Opportunities

Glutamine Deficiency Promotes Recurrence and Metastasis in Colorectal Cancer Through Enhancing Epithelial–mesenchymal Transition

Abstract 6741: Targeting glutamine metabolism potentiates antigen presentation in colorectal cancer

Immunosuppressive Immature Myeloid Cell Generation is Controlled by Glutamine Metabolism in Human Cancer.

Starve Cancer Cells of Glutamine: Break the Spell or Make a Hungry Monster?

Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer

Glutamine addiction promotes glucose oxidation in triple-negative breast cancer

Unbalanced Glutamine Partitioning between CD8T Cells and Cancer Cells Accompanied by Immune Cell Dysfunction in Hepatocellular Carcinoma

Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling